Accelerate Diagnostics, Inc.

NasdaqCM AXDX

Accelerate Diagnostics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -26.88 M

Accelerate Diagnostics, Inc. Operating Cash Flow is USD -26.88 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 35.99% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Accelerate Diagnostics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -41.99 M, a 17.86% change year over year.
  • Accelerate Diagnostics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -51.12 M, a -11.82% change year over year.
  • Accelerate Diagnostics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -45.72 M, a 15.20% change year over year.
  • Accelerate Diagnostics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -53.92 M, a 17.38% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
NasdaqCM: AXDX

Accelerate Diagnostics, Inc.

CEO Mr. Jack Phillips
IPO Date April 7, 1994
Location United States
Headquarters 3950 South Country Club Road
Employees 134
Sector Health Care
Industries
Description

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Similar companies

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

ANIK

Anika Therapeutics, Inc.

USD 15.58

-2.14%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

AXGN

AxoGen, Inc.

USD 18.24

-0.06%

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

AORT

Artivion, Inc.

USD 29.68

1.16%

CNMD

CONMED Corporation

USD 67.79

-2.46%

CVRX

CVRx, Inc.

USD 16.15

7.38%

LIVN

LivaNova PLC

USD 47.63

0.66%

IRMD

IRadimed Corporation

USD 57.52

1.79%

ELMD

Electromed, Inc.

USD 31.05

1.90%

AVNS

Avanos Medical, Inc.

USD 15.83

0.19%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

StockViz Staff

January 15, 2025

Any question? Send us an email